Hampton followed up with a thought about the Treat and Reduce Obesity Act (TROA) — a bipartisan bill in the U.S. Congress ...
Zacks Investment Research on MSN
Will Lower GLP-1 Prices Undermine Novo Nordisk's Near-Term Outlook?
Novo Nordisk NVO is a dominant player in the cardiometabolic space, which markets its blockbuster semaglutide-based (GLP-1) ...
Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war ...
Middle-class Indians trying to lose weight are embracing drugs such as Mounjaro in a country that has been called the world’s diabetes capital.
How long would you need to jab yourself...and contend with the cost? Two MDs specializing in weight loss and endocrinology share how it works.
The Trump administration has struck a deal to cut prices on popular weight loss drugs like Ozempic, expanding Medicare and Medicaid coverage to make them more affordable.
Preliminary research suggests that NG101, a drug from Neurogastrx, may lower the risk of nausea and vomiting in people taking ...
The Trump administration on Thursday announced a much-anticipated deal with drugmakers Eli Lilly and Novo Nordisk that aims to deliver lower prices for their popular GLP-1 drugs to certain Medicare ...
Even after Trump’s new deal, obesity drugs are still too expensive.
Eli Lilly and Novo Nordisk will lower prices for GLP-1 drugs, aligning with new drug pricing initiatives and Medicare Part D pilot coverage starting April 2026. Lilly's Zepbound and orforglipron will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback